MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock in private...
$74,999K
Net cash provided by
(used in) financing...
$74,870K
Canceled cashflow
$2K
Net decrease in
cash, cash...
-$226,613K
Canceled cashflow
$74,870K
Proceeds from maturities
of marketable...
$13,311K
Change in fair value of
warrant liabilities
$188,360K
Stock-based compensation
$8,870K
Non-cash lease expense
$109K
Depreciation expense
$28K
Repurchases of shares for tax
withholdings upon vesting of...
$2K
Net cash used in
investing activities
-$263,237K
Canceled cashflow
$13,311K
Net cash used in
operating activities
-$38,246K
Canceled cashflow
$197,367K
Purchases of marketable
securities
$276,500K
Purchases of property and
equipment
$48K
Net loss
-$219,585K
Accounts payable,
accrued liabilities and...
-$9,100K
Prepaid expenses and
other current assets
$6,359K
Interest amortization on
marketable securities
$488K
Operating lease
liabilities, net
-$61K
Other assets
$20K
Back
Back
Cash Flow
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)
source: myfinsight.com